High Pax3 expression characterizes a subset of human Brainstem Glioma. a-b Previously published expression profiles of human BSG and CG samples: post-treatment autopsy samples from St. Jude (a) and pre-treatment biopsy samples from Necker-Sick Children (b) were analyzed for gene expression differences as described in Materials and Methods. Log expression level of PAX3 in BSG versus CG. Red circles indicate the 11/28 (a) and 11/25 (b) of BSG samples with high PAX3 expression. c Table showing PAX3-High and PAX3-Low tumors from the dataset in (a) and their genetic alterations. Black squares indicate a sample is positive for that alteration. PDGFRA alteration includes PDGFRA gain, detected either by SNP array or FISH, or mutation (single nucleotide variants, indels, and structural variants), detected by whole-genome sequencing. d Age at diagnosis of PAX3-Low versus PAX3-High human BSG. e Schematic of the human brain showing the regional differences in Pax3 expression in glioma.